All In Biotech

NDA 204153 · Bausch

Luzu

Luliconazole · Topical · Azole Antifungal

Novel

Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Nov 14, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

11

1 Phase 3, 1 recruiting

FAERS reports

176

131 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 30, 2020.

Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . Luliconazole Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum. ( 1 )

Mechanism: Luliconazole Cream, 1% is an azole antifungal [see Microbiology ( 12.4 )]. Mechanism of Action Luliconazole is an antifungal that belongs to the azole class. Although the exact mechanism of action against dermatophytes is unknown, luliconazole appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LUZU · LULICONAZOLE 1% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Luliconazole" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective12
  • hepatic function abnormal9
  • nausea9
  • constipation8
  • pyrexia8
  • decreased appetite7
  • off label use7
  • diarrhoea6
  • pneumonia6
  • anaemia5
  • anxiety5
  • erythema5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20102
20125
20132
20146
201510
201626
20176
201813
201912
20204
202111
202221
202314
202415
202518
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Luzu (Luliconazole)

2024 spending

$6K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$8.03 per unit

View as table
YearSpending
2020$47,412
2021$40,721
2022$26,500
2023$18,074
2024$6,262

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.